Platform technology for the fast, accurate, and inexpensive extraction of multiomic information from DNA, RNA, and protein

Depixus has developed the MAGNA One platform, which utilizes Magnetic Force Spectroscopy (MFS) to provide unprecedented insights into biomolecular interactions. This innovative technology allows researchers to visualize and analyze thousands of individual biomolecular interactions in real-time, significantly enhancing the understanding of complex biological processes. MAGNA One is capable of studying a diverse range of biomolecules, including proteins, peptides, small molecules, and nucleic acids, enabling detailed investigations into molecular heterogeneity, dynamics, and rare events that are crucial for biological functions.

The MAGNA One platform is designed to facilitate high-resolution analysis at a massive scale, transforming molecular research and drug discovery. It offers the ability to probe the energetics of multi-way interactions and generate comprehensive kinetic and thermodynamic data. With its user-friendly interface and automated features, MAGNA One streamlines experimental design and sample preparation, making advanced molecular analysis accessible to a broader range of researchers. This technology not only improves the efficiency of research but also enhances the depth of insights, paving the way for significant advancements in fields such as biophysics and applied research.

France

Depixus SAS, based in Paris, is a life science technology company pioneering a groundbreaking technology based on magnetic force spectroscopy. This innovative technology provides real-time analysis of individual biomolecular interactions at scale, enabling researchers to decode disease mechanisms and unlock faster routes to more effective therapies.

Depixus

Company Details